Acquisition - February 9, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease.
Global report - February 9, 2026
Innovent and Lilly in strategic collaboration
Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.
Biotech Business - February 9, 2026
Carl Bennet invests SEK 45 million in Medivir
Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.
In a new job - February 5, 2026
Zelluna promotes Emilie Gauthy to Chief Technology Officer
Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.
Biotech Business - February 4, 2026
Cereno Scientific broadens development focus for CS014
Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Biotech Business - February 4, 2026
Abera Bioscience initiates new studies in pandemic influenza
The company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza.
